These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26026742)

  • 1. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.
    Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S
    ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
    Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
    Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
    Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
    World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.
    Yrjönen A; Koskenvuo L; Haapamäki C; Lepistö A
    Scand J Surg; 2024 Jun; 113(2):140-149. PubMed ID: 37828760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
    Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
    Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.
    Trilling B; Brind'Amour A; Hamad R; Tremblay JF; Dubé P; Mitchell A; Sidéris L
    World J Surg Oncol; 2021 Feb; 19(1):60. PubMed ID: 33622339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
    Trecourt A; Bakrin N; Glehen O; Gertych W; Villeneuve L; Isaac S; Benzerdjeb N; Fontaine J; Genestie C; Dartigues P; Leroux A; Quenet F; Marchal F; Odin C; Khellaf L; Svrcek M; Thierry S; Augros M; Omar A; Devouassoux-Shisheboran M; Kepenekian V;
    Ann Surg Oncol; 2024 May; 31(5):3325-3338. PubMed ID: 38341381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Pseudomyxoma Peritonei.
    Kusamura S; Delhorme JB; Taibi A; Villeneuve L; Deraco M; Dico RL; Glehen O; Moran B
    Ann Surg Oncol; 2024 Sep; 31(9):6262-6273. PubMed ID: 39008204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Blackham AU; Swett K; Eng C; Sirintrapun J; Bergman S; Geisinger KR; Votanopoulos K; Stewart JH; Shen P; Levine EA
    J Surg Oncol; 2014 Jun; 109(7):740-5. PubMed ID: 24375188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram to Predict Tube Occlusion During Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei.
    Liu Q; Li C; Wang B; Yu G
    J Coll Physicians Surg Pak; 2024 Jul; 34(7):790-794. PubMed ID: 38978242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival in patients with PMP: a single-institutional retrospective study from China.
    Yang R; Fu YB; Li XB; Ma R; Su YD; Wu HL; Liang XL; Li Y
    World J Surg Oncol; 2023 Oct; 21(1):347. PubMed ID: 37891655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix].
    Ma R; Li XB; Yan FC; Lin YL; Li Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):240-246. PubMed ID: 32306005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes and survival analysis of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei at a newly established peritoneal malignancy centre in Japan.
    Yano H; Gohda Y; Moran BJ; Suda R; Kokudo N
    Ann Gastroenterol Surg; 2024 Jul; 8(4):701-710. PubMed ID: 38957568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etiological analysis of infection after CRS + HIPEC in patients with PMP.
    Yang R; Zhao X; Fu YB; Lin YL; Ma R; Su YD; Wu HL; Liang XL; Li Y
    BMC Cancer; 2023 Sep; 23(1):903. PubMed ID: 37752468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.
    Zhao Q; Wei T; Ma R; Fu Y; Yang R; Su Y; Yu Y; Li B; Li Y
    Cancer Biol Med; 2024 Jul; 21(7):586-605. PubMed ID: 39026438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of Robot-Assisted Cytoreductive Surgery With Upper-Abdominal Peritonectomy for Pseudomyxoma Peritonei With Low Peritoneal Carcinomatosis Index: A Pilot Study.
    Fujimoto D; Yonemura Y; Taniguchi K; Kobayashi H
    Surg Laparosc Endosc Percutan Tech; 2024 Apr; 34(2):196-200. PubMed ID: 38417107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omental metastases in patients with pseudomyxoma peritonei or colorectal peritoneal metastases - is routine omentectomy justified?
    Enblad M; Birgisson H; Ghanipour L; Cashin P; Graf W
    Int J Hyperthermia; 2024; 41(1):2372356. PubMed ID: 38937059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transhepatic Bromelain and Acetylcysteine for Treatment of Posterior Gastric Pseudomyxoma Peritonei: A Case Report.
    Sun SL; Sarofim M; Morris DL
    Anticancer Res; 2024 May; 44(5):2239-2241. PubMed ID: 38677761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.